Pfizer Limited Stock Bombay S.E.

Equities

PFIZER

INE182A01018

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:50 2024-04-19 am EDT 5-day change 1st Jan Change
4,120 INR +0.30% Intraday chart for Pfizer Limited -0.98% -3.49%
Sales 2024 * 22.01B 264M Sales 2025 * 23.81B 286M Capitalization 189B 2.27B
Net income 2024 * 5.02B 60.18M Net income 2025 * 5.88B 70.54M EV / Sales 2024 * 8.59 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 7.94 x
P/E ratio 2024 *
37.7 x
P/E ratio 2025 *
32.2 x
Employees 1,702
Yield 2024 *
1.24%
Yield 2025 *
1.14%
Free-Float 35.19%
More Fundamentals * Assessed data
Dynamic Chart
Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer CI
Pfizer Limited Appoints Amit Agarwal as Whole-Time Director, Designated as Executive Director ­Finance CI
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer CI
Pfizer Limited Receives an Order from Joint Commissioner of State Tax Basis the GST Audit Conducted for Uttar Pradesh State for the Financial Year 2018-19 CI
Pfizer Limited Receives an Order from Deputy Commissioner of State Tax Basis the GST Audit Conducted for the Financial Year 2018-19 CI
Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024 CI
Pfizer Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Pfizer Ltd. Names CFO MT
Pfizer CFO Retires MT
Pfizer Limited Announces Retirement of Mr. Milind Patil as Chief Financial Officer CI
Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023 CI
Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023 CI
Pfizer Sees Sharp Fall in Fiscal Q2 Net Profit MT
Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors CI
Pfizer Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
More news
1 day+0.30%
1 week-0.98%
Current month-1.76%
1 month-4.89%
3 months-3.67%
6 months+4.08%
Current year-3.49%
More quotes
1 week
4 050.10
Extreme 4050.1
4 196.65
1 month
4 050.10
Extreme 4050.1
4 940.00
Current year
4 050.10
Extreme 4050.1
4 940.00
1 year
3 702.15
Extreme 3702.15
4 940.00
3 years
3 406.95
Extreme 3406.95
6 164.80
5 years
2 797.50
Extreme 2797.5
6 164.80
10 years
1 175.00
Extreme 1175
6 164.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 23-04-02
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - -
Members of the board TitleAgeSince
Chairman 71 99-12-06
Director/Board Member 74 12-05-20
Director/Board Member 64 15-02-13
More insiders
Date Price Change Volume
24-04-19 4,120 +0.30% 1,064
24-04-18 4,107 -0.18% 1,685
24-04-16 4,115 +0.32% 448
24-04-15 4,102 -1.41% 3,408
24-04-12 4,160 -0.64% 1,015

Delayed Quote Bombay S.E., April 19, 2024 at 06:00 am EDT

More quotes
Pfizer Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company has its own manufacturing facility at Goa. The Company has various independent contract/third party manufacturers based across India. Its product portfolio includes vaccine, anti-infectives, cardiac, pain, maternal nutrition, gastrointestinal, contraceptives, anti-inflammatory, nutrition and immunity, and respiratory. The Company's vaccine business is focused on Prevenar 13, a pneumococcal conjugate vaccine that is administered to infants who are six weeks and older as part of primary vaccination, toddlers, adolescents, adults, and elderly population. Its inflammation and immunology portfolio includes two advanced therapies, which cater to patients suffering from diseases related to chronic immune system such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis and ulcerative colitis.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Quarterly revenue - Rate of surprise